Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...
Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
In imported Lay's chips, traces of six allergens were found at once, which the manufacturer did not inform about on the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback